Pediatric non alcoholic fatty liver disease: more on novel treatment targets

BMC Pediatrics

Grazia Massa¹  Maria Sangermano¹  Cristina Pizza¹  Marco Poeta¹  Giulia Paolella¹  Pietro Vajro¹ 

[1] Department of Medicine and Surgery, University of Salerno, Via S. Allende, 84081, Baronissi -Salerno, Italy

关键词: Therapy;    Probiotics;    Microbiota;    Gut-liver axis;    Children;    Non alcoholic fatty liver disease;   

Others  :  1144680
DOI  :  10.1186/1471-2431-13-109

 received in 2013-05-21, accepted in 2013-07-18,  发布年份 2013

【 摘 要 】

The mainstay treatment of non alcoholic fatty liver disease (NAFLD) based on weight loss and/or lifestyle changes is most often unsuccessful at all ages, thus requiring the implementation of pharmacological strategies. Targeting insulin resistance and oxidative stress has recently proven unsatisfactory. Among a number of proposed innovative approaches targeting novel pathomechanisms, probiotics appear an interesting and reasonable option acting on gut-liver axis malfunction through the modulation of diet-driven, obesogenic, and inflammatory intestinal microbiota.

A combined multiple pharmacological therapy directed simultaneously towards novel and old pathomechanisms (including, e.g., insulin resistance, oxidative stress, gut-liver axis, apoptosis) along with lifestyle interventions however might be necessary both in adult and pediatric NAFLD therapy.

【 授权许可】

   
2013 Vajro et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Giorgio V, Prono F, Graziano F, Nobili V: Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013. in press
• [2]Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R: Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009, 139:905-911.
• [3]Vajro P, Paolella G, Fasano A: Microbiota and gut-liver axis: a mini-review on their influences on obesity and obesity related liver disease. J Pediatr Gastroenterol Nutr 2013, 56:461-468.
• [4]Vajro P, Lenta S, Pignata C, Salerno M, D'Aniello R, De Micco I, Paolella G, Parenti G: Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr 2012, 38:55. BioMed Central Full Text
• [5]Lirussi F, Mastropasqua E, Orando S, Orlando R: Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, CD005165.
• [6]Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J: Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011, 15:1090-1095.
• [7]Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R: Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011, 52:740-743.
• [8]Polyzos SA, Kountouras J, Zavos C, Deretzi G: Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012, 46:272-284.